ArchiveJanuary 2010

Primary EBV infection and MS

A NEW STUDY ON INITIAL EBV INFECTION AND MS Ascherio et al. Primary EBV infection and MS. Ann Neurol 2010; in press. “In this study all EBV-negative subjects (10 out of 10) who developed MS became EBV positive before MS onset. In contrast, only 36% (10 of the 28) controls subjects who were EBV-negative became EBV-positive with follow-up. Ascherio and colleagues conclude that MS risk is...

Which oral?

I am often asked which oral would you prescribe? There is no simple answer to this question. The answer will depend on several factors some of which are still to emerge; to mention a few: 1. If and when these agents get licensed and the conditions of licensing; i.e. a first- or second-line indication. 2. The price and more importantly the cost-effectiveness of the agents; NICE will dictate the...

SAFETY WARNING FOR NATALIZUMAB

EU RECOMMENDS MORE SAFETY WARNINGS FOR ELAN, BIOGEN’S TYSABRI 2010-01-21 18:28:09.776 GMT 21 January 2010; EMA/37607/2010: Press Office European Medicines Agency recommends additional measures to better manage risk of progressive multifocal leukoencephalopathy (PML) with Tysabri. The risk of PML increases after two years, but benefits of Tysabri continue to outweigh risks for patients with...

Translate

Categories

Recent Posts

Recent Comments

Archives